Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Benmelstobart by Apollomics for Small-Cell Lung Cancer: Likelihood of Approval
Benmelstobart is under clinical development by Apollomics and currently in Phase I for Small-Cell Lung Cancer. According to GlobalData, Phase...
Vebreltinib ER by Apollomics for Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis): Likelihood of Approval
Vebreltinib ER is under clinical development by Apollomics and currently in Phase II for Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis)....
Vebreltinib ER by Apollomics for Esophageal Cancer: Likelihood of Approval
Vebreltinib ER is under clinical development by Apollomics and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase...
Vebreltinib ER by Apollomics for Central Nervous System (CNS) Tumor: Likelihood of Approval
Vebreltinib ER is under clinical development by Apollomics and currently in Phase II for Central Nervous System (CNS) Tumor. According...
Vebreltinib ER by Apollomics for Pancreatic Cancer: Likelihood of Approval
Vebreltinib ER is under clinical development by Apollomics and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase...
Vebreltinib ER by Apollomics for Colon Cancer: Likelihood of Approval
Vebreltinib ER is under clinical development by Apollomics and currently in Phase II for Colon Cancer. According to GlobalData, Phase...
Geptanolimab by Apollomics for Non-Small Cell Lung Cancer: Likelihood of Approval
Geptanolimab is under clinical development by Apollomics and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData,...